Document is current
Any future updates will be listed below
-
Authors
Yosipovitch, Gil https://orcid.org/0000-0001-6303-1822
Gooderham, Melinda J.
Elmariah, Sarina B.
Bonfanti, Gianluca
Edwards, Roger A.
Gregoriou, Stamatios
Biswas, Pinaki
Myers, Daniela E.
Alderfer, Justine
Güler, Erman
Koulias, Christopher
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03720470 at ClinicalTrials.govnct04345367 at ClinicalTrials.govDocuments that mention this clinical trial
Itch Relief and Quality-of-Life Improvement with Abrocitinib and Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE COMPARE and JADE DARE
https://doi.org/10.1007/s40257-026-01030-5
Efficacy and Safety of Variable-Dose Versus Continuous-Dose Abrocitinib Treatment in Patients with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis
https://doi.org/10.1007/s13555-026-01778-y
Do Allergic Comorbidities Alter the Efficacy and Safety of Abrocitinib or Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis?
https://doi.org/10.1007/s13555-025-01516-w
Predicting Abrocitinib Efficacy at Week 12 Based on Clinical Response at Week 4: A Post Hoc Analysis of Four Randomized Studies in Moderate-to-Severe Atopic Dermatitis
https://doi.org/10.1007/s13555-024-01183-3
Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial
https://doi.org/10.1007/s40257-022-00738-4
Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program
https://doi.org/10.1007/s40257-021-00618-3
Rapidity of Improvement in Signs/Symptoms of Moderate-to-Severe Atopic Dermatitis by Body Region with Abrocitinib in the Phase 3 JADE COMPARE Study
https://doi.org/10.1007/s13555-022-00694-1
Documents that mention this clinical trial
Itch Relief and Quality-of-Life Improvement with Abrocitinib and Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE COMPARE and JADE DARE
https://doi.org/10.1007/s40257-026-01030-5
Efficacy and Safety of Variable-Dose Versus Continuous-Dose Abrocitinib Treatment in Patients with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis
https://doi.org/10.1007/s13555-026-01778-y
Do Allergic Comorbidities Alter the Efficacy and Safety of Abrocitinib or Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis?
https://doi.org/10.1007/s13555-025-01516-w
-
Funding
Funding for this research was provided by:
Pfizer
- License Information
-
More Information
Article History
Received: 13 July 2025
Accepted: 30 March 2026
First Online: 5 May 2026
Declarations
:
: Gil Yosipovitch is an Editorial Board member of American Journal of Clinical Dermatology. Gil Yosipovitch was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Gil Yosipovitch has been a consultant and an advisor for Pfizer Inc., AbbVie, Almirall, Amgen, Arcutis, Celldex, Eli Lilly, Escient Health, Galderma, GSK, Kiniksa, LEO Pharma, Merck, Novartis, Pierre Fabre, Sanofi-Regeneron, and Vifor, and a principal investigator for and grant recipient of Pfizer Inc., Eli Lilly, Escient Health, Galderma, Kiniksa, LEO Pharma, Novartis, Pierre Fabre, and Sanofi-Regeneron. Melinda J. Gooderham has received grants, personal fees, honoraria, and/or nonfinancial support from Pfizer Inc., AbbVie, Amgen, Akros Pharma, Arcutis, AnaptysBio, Aristea, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Dermavant, Dermira, Eli Lilly and Company, Galderma, JAMP Pharma, Janssen, Kyowa Kirin, LEO Pharma, MedImmune, Merck, MoonLake, Meiji, Nektar, Novartis, Roche, Sanofi-Genzyme, Regeneron Pharmaceuticals, Sun Pharma, UCB, Ventyx, and Bausch Health. Sarina B. Elmariah has been a consultant and an advisor for Pfizer Inc., Celldex, Galderma, Regeneron Pharmaceuticals, and Sanofi. Gianluca Bonfanti is a stakeholder of Engineering Ingegneria Informatica, a paid consultant contracted by Health Services Consulting Corporation in connection with this study. Health Services Consulting Corporation was a paid contractor to Pfizer Inc. in connection with the formal data analysis for this study. Roger A. Edwards is an employee of Health Services Consulting Corporation and received consultancy fees from Pfizer in connection with this study. Stamatios Gregoriou is or recently was a speaker and/or advisor for AbbVie, Eli Lilly & Co, LEO Pharma, Pfizer, Sanofi-Genzyme, and Janssen and has received research funding from AbbVie and Novartis. Pinaki Biswas, Daniela E. Myers, Justine Alderfer, Erman Güler, and Christopher Koulias are employees and shareholders of Pfizer Inc.
: Informed consent was obtained from all individual participants included in the study.
: Not applicable.
: All study documents and procedures were approved by the appropriate institutional review boards/ethics committees at each study site. The studies were conducted in compliance with the ethical principles from the Declaration of Helsinki and all International Council for Harmonisation Good Clinical Practice Guidelines. All local regulatory requirements were followed.
: Upon request, and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions, and exceptions, Pfizer may also provide access to the related individual de-identified participant data. See for more information.
: The following software application was used in the analysis for this manuscript: SAS 9.4.
: GB, RAE, PB, EG, and CK contributed to the study conceptualization and design. GB, RAE, and PB conducted the statistical analysis. All authors interpreted the data, provided critical feedback on the manuscript, approved the final manuscript for submission, and are accountable for the accuracy and integrity of the manuscript.
